Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $0.00 | $8.99M |
| Operating income | -$48.4M | -$78.2M | -$92.8M |
| Operating margin | — | — | -1031.5% |
| Net income | -$63.9M | -$71.1M | -$80.6M |
| Net margin | — | — | -896.1% |
| EPS (diluted) | -$38.17 | -$6.63 | -$2.24 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$37.4M | -$51.5M | -$81.6M |
| Capital expenditures | $166K | $366K | $719K |
| Free cash flow | -$37.5M | -$51.9M | -$82.3M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $21.6M | $354M | $189M |
| Total assets | $25.9M | $358M | $295M |
| Total liabilities | $66.6M | $35.1M | $22.8M |
| Long-term debt | $8.20M | $2.50M | $0.00 |
| Shareholders' equity | -$173M | $323M | $272M |
| Retained earnings | -$182M | -$253M | -$333M |
| Shares (wtd avg diluted) | 1.67M | 10.7M | 35.9M |
Every figure is extracted from BioAge Labs, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.